[HLA and thyroid cancer].
HLA typing was performed in 51 patients to analyse the pathogenetic background of differentiated and medullary thyroid carcinomas. A higher incidence of Bw62 and DR5 was observed in patients with papillary carcinoma (n = 24), DRw6 antigen in follicular carcinoma (n = 13), and DR3 antigen in patients with medullary carcinoma (n = 11). The DR3 antigen was present in one of two patients with a familial history of medullary thyroid carcinoma. Therefore, HLA typing is not suitable as a screening method for the detection of early thyroid carcinoma.
Dralle
H
H
Robin-Winn
M
M
Reilmann
L
L
Laue
A
A
Török
M
M
D000230:Adenocarcinoma / Q000235:genetics; D002277:Carcinoma / Q000235:genetics; D002291:Carcinoma, Papillary / Q000235:genetics; D002874:Chromosome Mapping; D005787:Gene Frequency; D006680:HLA Antigens / Q000235:genetics*; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D015236:HLA-C Antigens; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II / Q000235:genetics; D006801:Humans; D013964:Thyroid Neoplasms / Q000235:genetics*
D006680:HLA Antigens; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D015236:HLA-C Antigens; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II
HLA und Schilddrüsencarcinom.